1 otamine sulfate, platelet factor-4, and beta-thromboglobulin.

2 that observed for platelet factor 4 and beta-thromboglobulin.

3         As assessed by determination of beta-thromboglobulin and platelet factor 4 in the supernatant

4 pha-granule proteins platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor were

5 latelet count, platelet factor 4 (PF4), beta-thromboglobulin (beta-TG), and thromboxane B2 (TXB2).

6 -dimer (an index of thrombogenesis) and beta-thromboglobulin (beta-TG, a measure of platelet activati

7 complex [TAT]) and platelet activation (beta-thromboglobulin [beta-TG]) biomarkers were studied using

8 thrombin-antithrombin (TAT) complex and beta-thromboglobulin (betaTG) formation measured immediately

9 Fbeta1 protein were measured and plasma beta thromboglobulin (betaTG) levels were used as an indirect

10                      Platelet factor 4, beta-thromboglobulin (betaTG), platelet/endothelial cell adhe

11      In contrast, platelet factor 4 and beta-thromboglobulin do not appear to be affected.

12           Pl(A1/A2) genotype and plasma beta-thromboglobulin levels were determined in 439 incident C

13 telet activation, as measured by plasma beta-thromboglobulin levels, was not enhanced in individuals

14 nificantly higher platelet factor 4 and beta-thromboglobulin levels.

15 d, and had higher platelet factor 4 and beta-thromboglobulin levels; cardiovascular disease was minim

16 nterleukin-6, and platelet factor 4 and beta-thromboglobulin (markers of platelet activation).

17 heir products (e.g., platelet factor 4, beta-thromboglobulin, RANTES, thromboxane, or serotonin) in t

18               rTAP plus heparin reduced beta-thromboglobulin release; fibrinopeptide A concentrations

19                                  Plasma beta thromboglobulin was detected in platelet-depleted plasma

20 telet activation, platelet factor 4 and beta-thromboglobulin, were not increased in three patients wi